News >

Copanlisib Induces Nearly 1-Year Median PFS in Heavily Pretreated Indolent Lymphoma

Jason Harris
Published: Wednesday, Oct 11, 2017

Bruce D. Cheson, MD
Bruce D. Cheson, MD
Treatment with copanlisib (Aliqopa) led to a median progression-free survival (PFS) of 11.2 months and objective response rate (ORR) of 59.2% in patients with relapsed/refractory indolent lymphoma, according to results from the phase II CHRONOS-1 trial recently published in the Journal of Clinical Oncology.

“The drug is given weekly for 3 weeks, then a week off, then it’s given indefinitely, which is a burden on patients, particularly those who travel a distance to see their doctor,” Cheson said. “It’ll be challenging to get patients to be as compliant as you would like them to be, but I’m sure easier maintenance schedules will be developed to mitigate this problem.”
Dreyling M,, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published online October 4, 2017]. doi:10.1200/JCO.2017.75.4648.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x